Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patients
Not Applicable
Recruiting
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-jRCT1031210620
- Lead Sponsor
- Ohara Makoto
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 58
Inclusion Criteria
a diagnosis of type 2 diabetes mellitus
1) HbA1c 7.0% or more
2) treatment with DPP-4 inhibitors for 12weeks or longer
3) written informed consent
4) 20 years and over
Exclusion Criteria
1)the use of steroids or anti-inflammatory drugs,
2)diabetic ketosis and coma within 3 months before the study,
3)severe infection, severe trauma, pre-and post-operation,
4)an estimated glomerular filtration rate are within 30mL/min/1.73m2,
5)malignancy,
6)pregnancy
7)Patients who are judged as inappropriate for inclusion by phsicians
8)Patients using implantable medical devices such as cardiac pacemakers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary end point was d-ROMs change from baseline after completing 24 weeks of treatment intervention.
- Secondary Outcome Measures
Name Time Method 1)The change in glucose variability at 24 weeks from baseline<br>2) Inflammation markers and AGE-related markers<br>3) Glucose metabolism index, lipid metabolism index, Renal function, liver function<br>4) Eating Behavior Questionnaire and DTSQ<br>5) Blood pressure, pulse, weight